160 related articles for article (PubMed ID: 5580750)
1. Tolbutamide and diabetes.
Can Med Assoc J; 1971 Jun; 104(12):1067. PubMed ID: 5580750
[No Abstract] [Full Text] [Related]
2. Tolbutamide (Orinase) and diabetes.
Med Lett Drugs Ther; 1970 Nov; 12(24):97-8. PubMed ID: 5514167
[No Abstract] [Full Text] [Related]
3. [The venture of University Group Diabetes Program (UGDP). Some personal reflexions. Tolbutamide and phenformin under accusation].
Pirart J
Nouv Presse Med; 1972 Jan; 1(5):325-8. PubMed ID: 5010448
[No Abstract] [Full Text] [Related]
4. Status of problem of usage of tolbutamide. Preliminary statements.
Diabetes; 1970 Jun; 19(6):467-8. PubMed ID: 5467867
[No Abstract] [Full Text] [Related]
5. [Pancytopenia in diabetes mellitus treatment with tolbutamide?].
Traumann KJ; Grom E; Schwarzkopf H
Dtsch Med Wochenschr; 1975 Feb; 100(6):250-1. PubMed ID: 1112246
[TBL] [Abstract][Full Text] [Related]
6. Tolbutamide photosensitivity.
Kar PK; Das Gupta SK; Das KD
J Indian Med Assoc; 1984 Aug; 82(8):289-91. PubMed ID: 6491339
[No Abstract] [Full Text] [Related]
7. [Use of tolbutamide in diabetes and pregnancy].
Villanueva Gasca A; María García L; López Villegas J; Núñez E
Ginecol Obstet Mex; 1975 Aug; 38(226):133-7. PubMed ID: 1175987
[No Abstract] [Full Text] [Related]
8. Letter: Oral agents for diabetes.
Fisher AM
Can Med Assoc J; 1975 Sep; 113(5):364. PubMed ID: 1156963
[No Abstract] [Full Text] [Related]
9. [Are hypoglycemic sulfonamides dangerous?].
Aubertin MJ
Bord Med; 1972 Nov; 5(17):2287-90. PubMed ID: 4571486
[No Abstract] [Full Text] [Related]
10. [University Group Diabetes Program. The UGDP investigation remains clinically unacceptable].
Aarseth S
Tidsskr Nor Laegeforen; 1976 Aug; 96(22):1148. PubMed ID: 951693
[No Abstract] [Full Text] [Related]
11. Oral diabetic drugs again held hazardous.
J Tenn Med Assoc; 1975 Apr; 68(4):343. PubMed ID: 1117724
[No Abstract] [Full Text] [Related]
12. [Oral therapy in diabetes].
Kirkeby K
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1620-1. PubMed ID: 4588817
[No Abstract] [Full Text] [Related]
13. American diabetes association policy statement: the UGDP controversy.
Diabetes Care; 1979; 2(1):1-3. PubMed ID: 510102
[No Abstract] [Full Text] [Related]
14. Tolbutamide: more questions than answers.
Barclay WR
JAMA; 1971 Jan; 215(1):108-9. PubMed ID: 5107341
[No Abstract] [Full Text] [Related]
15. [Influencing the effect of Dirastan (tolbutamide) simultaneous administration of chloramphenicol in patients with diabetes and bacterial urinary tract inflammation (author's transl)].
Brunová E; Slabochová Z; Platilová H
Cas Lek Cesk; 1974 Jan; 113(3):72-5. PubMed ID: 4434411
[No Abstract] [Full Text] [Related]
16. [The treatment of diabetes by a single daily dose of tolbutamide].
Journ Annu Diabetol Hotel Dieu; 1967; 7():431-6. PubMed ID: 6058570
[No Abstract] [Full Text] [Related]
17. Medical guest editorial: The oral diabetic drug controversy.
Am Fam Physician; 1975 Dec; 12(6):73-4. PubMed ID: 1202930
[No Abstract] [Full Text] [Related]
18. [Tolbutamide-dimethyl-biguanide association in the treatment of diabetes mellitus].
Bernard C; Bernard R
Gaz Med Fr; 1965 Jul; 72(14):2763-5. PubMed ID: 5850517
[No Abstract] [Full Text] [Related]
19. A note on tolbutamide and diabetes.
Med Lett Drugs Ther; 1970 Jul; 12(14):60. PubMed ID: 4935987
[No Abstract] [Full Text] [Related]
20. Nine years' experience with tolbutamide in the treatment of diabetes.
Balodimos MC; Camerini-Dávalos RA; Marble A
Metabolism; 1966 Nov; 15(11):957-70. PubMed ID: 5950894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
